CoChat
Sign Up
Cited by 36Protease and Inhibitor MechanismsRenin-Angiotensin System StudiesBlood Coagulation and Thrombosis Mechanisms

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

YC-1 [3-(5′-Hydroxymethyl-2′-furyl)-1-benzyl Indazole] Inhibits Neointima Formation in Balloon-Injured Rat Carotid through Suppression of Expressions and Activities of Matrix Metalloproteinases 2 and 9

Liu, Yi-Nan, Pan, Shiow-Lin, Peng, Chieh-Yu, Guh, Jih-Hwa, Huang, Dong-Ming, Chang, Ya-Ling, Lin, Chun-Hung, Pai, Hui-Chen, Kuo, Sheng-Chu, Lee, Fang-Yu, Teng, Che-Ming·2006·The Journal of Pharmacology and Experimental Therapeutics
DOI 10.1124/jpet.105.090563
Open this paper in CoChat — free account

Abstract

Matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, and postrevascularization production of vascular smooth muscle cells may play key roles in development of arterial restenosis. We investigated the inhibitory effect of 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1), a benzyl indazole compound, on MMP-2 and MMP-9 activity in a balloon-injury rat carotid artery model. Injury was induced by inserting a balloon catheter through the common carotid artery; after 14 days, histopathological analysis using immunostaining and Western blotting revealed significant restenosis with neointimal formation that was associated with enhanced protein expression of MMP-2 and MMP-9. However, these effects were dose-dependently reduced by orally administered YC-1 (1-10 mg/kg). In addition, gelatin zymography demonstrated that increased MMP-2 and MMP-9 activity was diminished by YC-1 treatment. On the other hand, YC-1 inhibited hydrolysis of the fluorogenic quenching substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH(2) by recombinant MMP-2 and MMP-9 with IC(50) values = 2.07 and 8.20 muM, respectively. Reverse transcription-polymerase chain reaction analysis of MMP-2 and MMP-9 mRNA revealed that YC-1 significantly inhibited mRNA levels of MMPs. Finally, for the YC-1 treatment group, we did not observe elevation of cGMP levels using enzyme-linked immunosorbent assay, suggesting that YC-1 inhibition of neointimal formation is not through a cGMP-elevating pathway. These data show YC-1 s…

Overview

Integrity signals

Registry

Crossref · 10.1124/jpet.105.090563

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • YC-1 interacts with several non-HIF targets, complicating attribution of its biological effects solely to HIF inhibition.

    “In addition, YC-1 is known to interact with several non-HIF targets, complicating attribution of its biological effects solely to HIF inhibition [405,406].”

    From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [406]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 29

  1. Bendeck MP, Zempo N, Clowes AW, Galardy RE, and Reidy MA (1994) Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 75: 539–545. · DOI
  2. Bult H (2000) Restenosis: a challenge for pharmacology. Trends Pharmacol Sci 21: 274–279. · DOI
  3. Cho A and Reidy MA (2002) Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res 91: 845–851. · DOI
  4. Di Fulvio M, Lauf PK, and Adragna NC (2001) Nitric oxide signaling pathway regulates potassium chloride cotransporter-1 mRNA expression in vascular smooth muscle cells. J Biol Chem 276: 44534–44540. · DOI
  5. Galis ZS, Asanuma K, Godin D, and Meng X (1998) N- Acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy? Circulation 97: 2445–2453. · DOI
  6. Galis ZS and Khatri JJ (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad and the ugly. Circ Res 90: 251–262. · DOI
  7. Galle J, Zabel U, Hubner U, Hatzelmann A, Wagner B, Wanner C, and Schmidt HH (1999) Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol 127: 195–203. · DOI
  8. Garas SM, Huber P, and Scott NA (2001) Overview of therapies for prevention of restenosis after coronary interventions. Pharmacol Ther 92: 165–178. · DOI
  9. Gomez MP and Nasi E (2000) Light transduction in invertebrate hyperpolarizing photoreceptors: possible involvement of a Go-regulated guanylate cyclase. J Neurosci 20: 5254–5263. · DOI
  10. Imai T, Morita T, Shindo T, Nagai R, Yazaki Y, Kurihara H, Suematsu M, and Katayama S (2001) Vascular smooth muscle cell-directed overexpression of heme oxygenase-1 elevates blood pressure through attenuation of nitric oxide-induced vasodilation in mice. Circ Res 89: 55–62. · DOI
  11. Kuzuya M and Iguchi A (2003) Role of matrix metalloproteinases in vascular remodeling. J Atheroscler Thromb 10: 275–282. · DOI
  12. Lange RA, Flores ED, and Hillis LD (1991) Restenosis after coronary balloon angioplasty. Annu Rev Med 42: 127–132. · DOI
  13. Lijnen HR, Lupu F, Moons L, Carmeliet P, Goulding D, and Collen D (1999) Temporal and topographic matrix metalloproteinase expression after vascular injury in mice. Thromb Haemost 81: 799–807. · DOI
  14. Liu MW, Roubin GS, and King SB 3rd (1989) Restenosis after coronary angioplasty. Circulation 79: 1374–1387. · DOI
  15. Mulsch A, Bauersachs J, Schafer A, Stasch JP, Kast R, and Busse R (1997) Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol 120: 681–689. · DOI
  16. Pan SL, Guh JH, Peng CY, Chang YL, Cheng FC, Chang JH, Kuo SC, Lee FY, and Teng CM (2005) A potential role of YC-1 on the inhibition of cytokine release in peripheral blood mononuclear leukocytes and endotoxemic mouse models. Thromb Heamost 93: 940–948. · DOI
  17. Pan SL, Huang YW, Guh JH, Chang YL, Peng CY, and Teng CM (2003) Esculetin inhibits Ras-mediated cell proliferation and attenuates vascular restenosis following angioplasty in rats. Biochem Pharmacol 65: 1897–1905. · DOI
  18. Pauletto P, Sartore S, and Pessina AC (1994) Smooth-muscle-cell proliferation and differentiation in neointima formation and vascular restenosis. Clin Sci 87: 467–479. · DOI
  19. Pauly RR, Passaniti A, Bilato C, Monticone R, Cheng L, Papadopoulos N, Gluzband YA, Smith L, Weinstein C, and Lakatta EG (1994) Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res 75: 41–54. · DOI
  20. Ramnath N and Creaven PJ (2004) Matrix metalloproteinase inhibitors. Curr Oncol Rep 6: 96–102. · DOI
  21. Southgate KM, Fisher M, Banning AP, Thurston VJ, Baker AH, Fabunmi RP, Groves PH, Davies M, and Newby AC (1996) Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. Circ Res 79: 1177–1187. · DOI
  22. Suzuki T, Suematsu M, and Makino R (2001) Organic phosphates as a new class of soluble guanylate cyclase inhibitors. FEBS Lett 507: 49–53. · DOI
  23. Tulis DA, Bohl Masters KS, Lipke EA, Schiesser RL, Evans AJ, Peyton KJ, Durante W, West JL, and Schafer AI (2002) YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function. Biochem Biophys Res Commun 291: 1014–1021. · DOI
  24. Tulis DA, Durante W, Peyton KJ, Chapman GB, Evans AJ, and Schafer AI (2000) YC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation. Biochem Biophys Res Commun 279: 646–652. · DOI
  25. Wegener JW, Gath I, Forstermann U, and Nawrath H (1997) Activation of soluble guanylyl cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from rat. Br J Pharmacol 122: 1523–1529. · DOI
  26. Wegener JW and Nawrath H (1997) Differential effects of isoliquiritigenin and YC-1 in rat aortic smooth muscle. Eur J Pharmacol 323: 89–91. · DOI
  27. Wu CC, Ko FN, Kuo SC, Lee FY, and Teng CM (1995) YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol 116: 1973–1978. · DOI
  28. Wu CH, Chang WC, Chang GY, Kuo SC, and Teng CM (2004) The inhibitory mechanism of YC-1, a benzyl indazole, on smooth muscle cell proliferation: an in vitro and in vivo study. J Pharmacol Sci 94: 252–260. · DOI
  29. Yukihiro H, Ikeda U, Katsuki T, Mizuno O, Fujikawa H, and Shimada K (2001) Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. Atherosclerosis 161: 185–192. · DOI

Cited by

Sorted by citations

Metadata

Authors
Liu, Y.-N., Pan, S.-L., Peng, C.-Y., Guh, J.-H., Huang, D.-M., Chang, Y.-L., Lin, C.-H., Pai, H.-C., Kuo, S.-C., Lee, F.-Y., & Teng, C.-M.
Affiliations
National Taiwan University (TW)
ORCID
Venue
The Journal of Pharmacology and Experimental Therapeutics
Publisher
Elsevier BV
Published
2006-01
Volume
316
Issue
1
Pages
35-41
ISSN
0022-3565 (ISSN-L)
DOI
10.1124/jpet.105.090563
OpenAlex
W2149407335
Cited by
36
References
1
Citations by year
2026: 1 · 2024: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2015: 1 · 2014: 1 · 2013: 2 · 2012: 3
FWCI
1.50
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Keywords
YC-1, neointima formation, restenosis, MMP-2, MMP-9, balloon injury, carotid artery, vascular smooth muscle cells, angioplasty
MeSH terms
Animals, Carotid Arteries, Catheterization, Enzyme-Linked Immunosorbent Assay, Fluorescent Dyes, Cyclic GMP, Immunohistochemistry, Indazoles, Male, Neovascularization, Pathologic, RNA, Messenger, Rats, Wistar, Reverse Transcriptase Polymerase Chain Reaction, Angiogenesis Inhibitors, Matrix Metalloproteinase 2, Matrix Metalloproteinase 9, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review